Literature DB >> 11996829

Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants.

N Butz1, C Porté, H Courrier, M P Krafft, Th F Vandamme.   

Abstract

Pulmonary administration of drugs has demonstrated numerous advantages in the treatment of pulmonary diseases due to direct targeting to the respiratory tract. It enables avoiding the first pass effect, reduces the amount of drugs administered, targets drugs to specific sites and reduces their side effects. Reverse water-in-fluorocarbon (FC) emulsions are potential drug delivery systems for pulmonary administration using pressurized metered-dose inhalers (pMDI). The external phase of these emulsions consists of perfluorooctyl bromide (PFOB, perflubron), whereas their internal phase contains the drugs solubilized or dispersed in water. These emulsions are stabilized by a perfluoroalkylated dimorpholinophosphate (F8H11DMP), i.e. a fluorinated surfactant. This study demonstrates the possibility of delivering a reverse fluorocarbon emulsion via the pulmonary route using a CFC-free pMDI. Two hydrofluoroalkanes (HFAs) (Solkane(R) 134a and Solkane(R) 227) were used as propellants, and various solution (or emulsion)/propellant ratios (1/3, 1/2, 2/3, 1/1, 3/2, 3/1 v/v) were investigated. The insolubility of water (with or without the fluorinated surfactant F8H11DMP) in both HFA 227 and HFA 134a was demonstrated. PFOB and the reverse emulsion were totally soluble or dispersible in all proportions in both propellants. This study demonstrated also that the reverse FC emulsion can be successfully used to deliver caffeine in a homogeneous and reproducible way. The mean diameter of the emulsion water droplets in the pressured canister was investigated immediately after packaging and after 1 week of storage at room temperature. Best results were obtained with emulsion/propellant ratios comprised between 2/3 and 3/2, and with HFA 227 as propellant.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11996829     DOI: 10.1016/s0378-5173(02)00086-8

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

Review 1.  Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.

Authors:  Cheng Loong Ngan; Azren Aida Asmawi
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 2.  Advances in metered dose inhaler technology: formulation development.

Authors:  Paul B Myrdal; Poonam Sheth; Stephen W Stein
Journal:  AAPS PharmSciTech       Date:  2014-01-23       Impact factor: 3.246

3.  Synthesis, physicochemical properties and in vitro cytotoxicity of nicotinic acid ester prodrugs intended for pulmonary delivery using perfluorooctyl bromide as vehicle.

Authors:  Hans-Joachim Lehmler; Ling Xu; Sandhya M Vyas; Vivian A Ojogun; Barbara L Knutson; Gabriele Ludewig
Journal:  Int J Pharm       Date:  2007-11-17       Impact factor: 5.875

4.  Perfluoroalkyl chemicals and asthma among children 12-19 years of age: NHANES (1999-2008).

Authors:  Olivier Humblet; Ledif Grisell Diaz-Ramirez; John R Balmes; Susan M Pinney; Robert A Hiatt
Journal:  Environ Health Perspect       Date:  2014-06-06       Impact factor: 9.031

5.  Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers.

Authors:  Zhengwei Huang; Lei Shu; Ying Huang; Chuanbin Wu; Xin Pan
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-23

Review 6.  Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases.

Authors:  Malgorzata Smola; Thierry Vandamme; Adam Sokolowski
Journal:  Int J Nanomedicine       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.